Issuer: Lifecare ASA
Ex. date: 21 May 2024
Type of corporate action: Preferential rights issue
Other information: The shares in Lifecare ASA will from today, 21 May 2024, be
traded exclusive of the right to receive subscription rights for shares in the
preferential rights issue announced on 25 April 2024.
This information is published in accordance with the requirements of the
Continuing Obligations for Euronext Growth Oslo.
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare ASA, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2024-05-21 08:00 CEST.